Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain ...

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...